Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.23 million versus the consensus estimate of $7.07 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.